Literature DB >> 28647210

High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.

Yanming Liu1, Feiyue Zhang2, Zhaobo Zhang3, Daoqing Wang4, Baojuan Cui4, Fanshuo Zeng4, Laigang Huang4, Qi Zhang4, Qiangsan Sun5.   

Abstract

Cysteine Rich Angiogenic Inducer 61 (Cyr61) and Vascular Endothelial Growth Factor (VEGF) are signaling proteins involved in the regulation of tumor angiogenesis and progression. The purpose of this study was to investigate the clinicopathological and prognostic significance of Cyr61 and VEGF expressions in osteosarcoma. Immunohistochemical staining was performed to evaluate the expression of both the proteins in 84 osteosarcoma samples. Correlation between Cyr61/VEGF expressions and clinicopathological parameters was determined using Rank sum test and Spearman's rank correlation coefficient. Prognostic factors were identified using univariate and multivariate Cox regression analysis. The expressions of Cyr61 and VEGF were weak in 26.2% and 17.9%, moderate in 26.2% and 23.8%, and strong in 47.6% and 58.3% of osteosarcoma samples, respectively. Cyr61 and VEGF expressions moderately correlated with each other in osteosarcoma, and exhibited significant association with Enneking stage and distant metastasis. In addition, the high expression of both proteins significantly correlated with short overall survival time in these patients. The key finding in this study was that both Cyr61 and VEGF expressions were independent prognostic indicators of overall survival. In summary, our results indicate that expression of Cyr61 and VEGF may serve as important prognostic predictors in patients with osteosarcoma.
Copyright © 2017. Published by Elsevier GmbH.

Entities:  

Keywords:  Cyr61; Osteosarcoma; Prognostic indicator; VEGF

Mesh:

Substances:

Year:  2017        PMID: 28647210     DOI: 10.1016/j.prp.2017.06.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  16 in total

1.  [Angiotensin Ⅱ induces apoptosis of HEK293T cells by up-regulating Cyr61 expression].

Authors:  Junjie Wang; Yan Jiang; Senouthai Soulixay; Dongdong Fu; Yanwu You
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

2.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

3.  Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Authors:  Huensuk Kim; Seungyeul Yoo; Ruoji Zhou; An Xu; Jeffrey M Bernitz; Ye Yuan; Andreia M Gomes; Michael G Daniel; Jie Su; Elizabeth G Demicco; Jun Zhu; Kateri A Moore; Dung-Fang Lee; Ihor R Lemischka; Christoph Schaniel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

4.  Efficacy of ifosfamide combined with liposome doxorubicin on osteosarcoma and its effects on serum IL-10, TNF-α, and IFN-γ in patients with osteosarcoma.

Authors:  Guilin Huang; Sha Hua; Heming Liu; Haizhen Zhou; Xiujin Chen; Zhichou Wang; Wenxing Yu
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

5.  Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines.

Authors:  Jordan Ayers; Rowan J Milner; Galaxia Cortés-Hinojosa; Alberto Riva; Sandra Bechtel; Bikash Sahay; Matthew Cascio; Amandine Lejeune; Keijiro Shiomitsu; Carlos Souza; Oscar Hernandez; Marc Salute
Journal:  J Vet Diagn Invest       Date:  2021-01-15       Impact factor: 1.279

6.  LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism.

Authors:  Jinxue Zhang; Yuan Zhang; Shiyang Cheng; Yang Mu; Yongming Liu; Xin Yi; Dongxu Jiang; Yong Ding; Ran Zhuang
Journal:  World J Surg Oncol       Date:  2020-06-20       Impact factor: 2.754

7.  Identification of the Transcriptional Networks and the Involvement in Angiotensin II-Induced Injury after CRISPR/Cas9-Mediated Knockdown of Cyr61 in HEK293T Cells.

Authors:  Junjie Wang; Dongdong Fu; Soulixay Senouthai; Yan Jiang; Rentong Hu; Yanwu You
Journal:  Mediators Inflamm       Date:  2019-04-15       Impact factor: 4.711

8.  Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis.

Authors:  Francesca Perut; Laura Roncuzzi; Nicoletta Zini; Annamaria Massa; Nicola Baldini
Journal:  Cancers (Basel)       Date:  2019-06-05       Impact factor: 6.639

9.  Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.

Authors:  Ling-Yu Chu; Jian-Yuan Zhou; Yi-Xuan Zhao; Yan-Ting Ou; Tian Yang; Yu-Hui Peng; Wang-Kai Fang; Yi-Wei Xu; Jian-Jun Xie
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

Review 10.  The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review.

Authors:  Argyris C Hadjimichael; Athanasios F Foukas; Olga D Savvidou; Andreas F Mavrogenis; Amanda K Psyrri; Panayiotis J Papagelopoulos
Journal:  Clin Sarcoma Res       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.